SAVOIR: Savolitinib vs Sunitinib in MET-Driven Papillary Renal Cell Carcinoma

May 29-31, 2020; Online at meetings.asco.org/am
Savolitinib demonstrated promising improvements in PFS, OS, and response rate with favorable safety outcomes vs sunitinib.
Format: Microsoft PowerPoint (.ppt)
File Size: 242 KB
Released: June 1, 2020

Acknowledgements

Provided by Clinical Care Options, LLC.

Contact Clinical Care Options

For customer support please email: customersupport@cealliance.com

Mailing Address
Clinical Care Options, LLC
12001 Sunrise Valley Drive
Suite 300
Reston, VA 20191

Supported by educational grants from
AstraZeneca
Bayer HealthCare Pharmaceuticals Inc.
Bristol-Myers Squibb
Exelixis
Pfizer, Inc. and EMD Serono

Related Content

Phase III COSMIC-313: addition of cabozantinib to nivolumab plus ipilimumab in previously untreated patients with IMDC intermediate- or poor-risk advanced RCC, presented at ESMO 2022 and reported by Clinical Care Options (CCO)

Released: September 22, 2022

Results from CheckMate 914 (Part A): adjuvant nivolumab plus ipilimumab vs placebo in resected stage II/III clear-cell RCC at high risk of recurrence, presented at ESMO 2022 and reported by Clinical Care Options (CCO)

Released: September 19, 2022

Experts highlight key studies being reported at the upcoming 2022 ESMO Congress in this commentary from Clinical Care Options (CCO)

Nicoletta Colombo, MD Robert Motzer, MD David Planchard, MD, PhD Elizabeth R. Plimack, MD, MS Rachna Shroff, MD Sara Tolaney, MD, MPH Released: September 8, 2022

Expert faculty discuss key updates on treatment options in renal cell carcinoma, from Clinical Care Options (CCO)

Katy Beckermann, MD, PhD person default Naomi B. Haas, MD Eric Jonasch, MD Released: August 1, 2022

Leaving the CCO site

You are now leaving the CCO site. The new destination site may have different terms of use and privacy policy.

Continue

Cookie Settings